ChemoCentryx $69M Securities Class Action Settlement

ChemoCentryx $69M Securities Class Action SettlementInvestors who bought ChemoCentryx stock between Nov. 26, 2019, and May 6, 2021, may be eligible to claim a cash payment from a class action settlement.ChemoCentryx $69M Securities Class Action SettlementWeekly NewsletterClass actions settlements delivered to your inbox.Thank you! Check your inbox for a welcome email.Oops! Something went wrong while submitting the form.William C. GendronEditor in ChiefPublishedJuly 27, 2026 1:18 PMUpdatedAugust 24, 2026Join the DiscussionInvestors who purchased or otherwise acquired ChemoCentryx Inc. common stock between Nov. 26, 2019, and May 6, 2021, may be eligible to claim a cash payment from a class action settlement.ChemoCentryx Inc. and its former CEO Thomas J. Schall agreed to pay $69 million to settle a securities class action lawsuit alleging they made material misrepresentations about the company's Advocate study, the Phase 3 clinical trial of its vasculitis drug avacopan and its communications with the Food and Drug Administration about the drug's approval.Who can file a claim?The settlement class includes all persons who purchased or otherwise acquired ChemoCentryx common stock between Nov. 26, 2019, and May 6, 2021, inclusive, and suffered damaged.Additional detailsBoth individuals and entities can be class members.Each separate legal entity or separately managed account must submit a separate claim.The beneficial owner, not the record owner, must sign the claim form, and all joint beneficial owners must sign.Agents, executors, administrators, guardians and trustees may submit claims on behalf of others and must provide proof of authority.Participants in and beneficiaries of any employee retirement or benefit plan covered by ERISA should report only shares purchased or held outside the plan on an individual claim form.Plan trustees may submit claims for shares purchased or held through an ERISA plan.How much can class members get?